Cowen & Co. Upgrades Alimera Sciences Inc to Outperform

Brokerage firm Cowen & Co. Upgrades its rating on Alimera Sciences Inc(NASDAQ:ALIM). The shares have been rated Outperform. Previously, the analysts had a Market Perform rating on the shares. The rating by Cowen & Co. was issued on Sep 16, 2016.

Alimera Sciences Inc (ALIM) shares turned negative on Thursdays trading session with the shares closing down -0.02 points or -1.21% at a volume of 3,83,147. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $1.67. The peak price level was also seen at $1.67 while the days lowest was $1.62. Finally the shares closed at $1.63. The 52-week high of the shares is $5.15 while the 52-week low is $1.015. According to the latest information available, the market cap of the company is $75 M.

Alimera Sciences Inc(ALIM) last announced its earnings results on Aug 3, 2016 for Fiscal Year 2016 and Q2.Company reported revenue of $9.56M. Analysts had an estimated revenue of $8.42M. Earnings per share were $-0.17. Analysts had estimated an EPS of $-0.19.

Several Insider Transactions has been reported to the SEC. On Dec 17, 2015, Richard S Jr Eiswirth (COO and CFO) sold 46,669 shares at $2.31 per share price.Also, On Nov 16, 2015, C. Daniel Myers (President and CEO) sold 2,000 shares at $4.37 per share price.On Sep 8, 2015, Calvin W. Roberts (director) purchased 6,424 shares at $3.00 per share price, according to the Form-4 filing with the securities and exchange commission.

Alimera Sciences Inc. (Alimera) is a pharmaceutical company. The Company is engaged in the research development and commercialization of prescription ophthalmic pharmaceuticals. The Company focuses on diseases affecting the back of the eye or retina. The Company’s commercial product is ILUVIEN which has been developed to treat diabetic macular edema (DME). ILUVIEN has received marketing authorization in the United States Austria Belgium the Czech Republic Denmark Finland France Germany Ireland Italy Luxembourg the Netherlands Norway Portugal Spain Sweden and the United Kingdom. In the United States ILUVIEN is indicated for the treatment of DME in patients who have been previously treated with a course of corticosteroids and did not have a rise in intraocular pressure (IOP). In the EU countries it is indicated for the treatment of vision impairment associated with DME.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *